Aqueous radiation protecting formulations and methods for making and using them
View Patent ↗Medical devices are typically sterilized in processes used to manufacture such products and their sterilization by exposure to radiation is a common practice. Radiation has a number of advantages over other sterilization processes including a high penetrating ability, relatively low chemical reactivity, and instantaneous effects without the need to control temperature, pressure, vacuum, or humidity. Unfortunately, radiation sterilization can compromise the function of certain components of medical devices. For example, radiation sterilization can lead to loss of protein activity and/or lead to bleaching of various dye compounds. Embodiments of the invention provide methods and materials that can be used to protect medical devices from unwanted effects of radiation sterilization.
1. A method of inhibiting damage to a saccharide sensor that can result from a radiation sterilization process, the method comprising combining the saccharide sensor with an aqueous radioprotectant formulation during the sterilization process, wherein:
the saccharide sensor comprises a saccharide binding polypeptide having a carbohydrate recognition domain;
the aqueous radioprotectant formulation comprises a saccharide selected for its ability to bind the saccharide binding polypeptide; and
performing the sterilization process under conditions selected so that the saccharide binds the saccharide binding polypeptide, thereby inhibiting damage to the saccharide sensor that can result from the radiation sterilization process.
2. The method of claim 1 , wherein the saccharide binding polypeptide comprises mannan binding lectin, concanavalin A or glucose oxidase.
3. The method of claim 1 , wherein the saccharide comprises glucose, mannose, fructose, melizitose, N-acetyl-D-glucosamine, sucrose or trehalose.
4. The method of claim 1 , wherein the aqueous radioprotectant formulation comprises an antioxidant selected from the group consisting of ascorbate, urate, nitrite, vitamin E, α-tocopherol or nicotinate methylester.
5. The method of claim 1 , wherein:
the saccharide sensor comprises a fluorophore; and
the aqueous radioprotectant formulation comprises a fluorophore quenching composition selected for its ability to quench the fluorophore.
6. The method of claim 1 , wherein the aqueous radioprotectant formulation comprises a buffering agent.
7. The method of claim 6 , wherein the buffering agent is selected from the group consisting of citrate, tris(hydroxymethyl)aminomethane (TRIS) and tartrate.
8. The method of claim 1 , wherein the radiation sterilization process comprises a single dose of radiation.
9. The method of claim 1 , wherein the radiation sterilization process comprises electron beam irradiation.
10. A composition of matter comprising:
a saccharide sensor comprising:
a saccharide binding polypeptide having a carbohydrate recognition domain; and
a fluorophore; and
an aqueous radioprotectant formulation comprising:
a saccharide, wherein the saccharide is bound to the carbohydrate recognition domain;
an antioxidant compound, wherein the antioxidant compound is selected from the group consisting of ascorbate, urate, nitrite, vitamin E, α-tocopherol or nicotinate methylester; and
a fluorophore quenching composition.
11. The composition of claim 10 , wherein the fluorophore quenching composition comprises acetaminophen.
12. The composition of claim 11 , wherein the aqueous radioprotectant formulation comprises acetaminophen in a concentration of at least 1 mM to 50 mM.
13. The composition of claim 10 , wherein the aqueous radioprotectant formulation comprises ascorbate in a concentration of at least 1 mM to 100 mM.
14. The composition of claim 10 , wherein the saccharide is selected from the group consisting of glucose, mannose, fructose, melizitose, N-acetyl-D-glucosamine, sucrose or trehalose.
15. The composition of claim 14 , wherein the aqueous radioprotectant formulation comprises mannose in a concentration of at least 1 mM to 100 mM.
16. The composition of claim 14 , wherein the aqueous radioprotectant formulation comprises sucrose in a concentration of at least 10 mM to 1000 mM.
17. The composition of claim 10 , wherein the aqueous radioprotectant formulation comprises a buffering agent; and has a pH of 6 or below.
18. The composition of claim 17 , wherein the buffering agent is selected from the group consisting of citrate, tris(hydroxymethyl)aminomethane (TRIS) and tartrate.
19. The composition of claim 10 , wherein the aqueous radioprotectant formulation comprises a surfactant.